poisar

Stocks · News reference

ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer

Benzinga Newsdesk

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ALXO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — ALX ONCOLOGY HOLDINGS INC (ALXO)

    Filed: 2026-10-15 AccNo: 0001193125-26-422992 Size: 460 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

    ALXO